Targeting adhesion signaling in KRAS, LKB1 mutant lung adenocarcinoma
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Loss of LKB1 activity is prevalent in KRAS mutant lung adenocarcinoma and promotes aggressive and treatment-resistant tumors. Previous studies have shown that LKB1 is a negative regulator of the focal adhesion kinase (FAK), but in vivo studies testing the efficacy of FAK inhibition in LKB1 mutant cancers are lacking. Here, we took a pharmacologic approach to show that FAK inhibition is an effective early-treatment strategy for this high-risk molecular subtype. We established a lenti-Cre–induced Kras and Lkb1 mutant genetically engineered mouse model ( KL Lenti ) that develops 100% lung adenocarcinoma and showed that high spatiotemporal FAK activation occurs in collective invasive cells that are surrounded by high levels of collagen. Modeling invasion in 3D, loss of Lkb1 , but not p53 , was sufficient to drive collective invasion and collagen alignment that was highly sensitive to FAK inhibition. Treatment of early, stage-matched KL Lenti tumors with FAK inhibitor monotherapy resulted in a striking effect on tumor progression, invasion, and tumor-associated collagen. Chronic treatment extended survival and impeded local lymph node spread. Lastly, we identified focally upregulated FAK and collagen-associated collective invasion in KRAS and LKB1 comutated human lung adenocarcinoma patients. Our results suggest that patients with LKB1 mutant tumors should be stratified for early treatment with FAK inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling
Platt, R. J., Chen, S., Zhou, Y., Yim, M. J., Swiech, L., Kempton, H. R., Dahlman, J. E., Parnas, O., Eisenhaure, T. M., Jovanovic, M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.014 · Cited by 2,001
Collagen reorganization at the tumor-stromal interface facilitates local invasion
Provenzano, P. P., Eliceiri, K. W., Campbell, J. M., Inman, D. R., White, J. G., & Keely, P. J. (2006) · BMC Medicine · doi:10.1186/1741-7015-4-38 · Cited by 1,804
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.029 · Cited by 1,789
FAK in cancer: mechanistic findings and clinical applications
Sulzmaier, F. J., Jean, C., & Schlaepfer, D. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3792 · Cited by 1,381 · cited 3×
“To facilitate the translation of our results into human trials, mice were treated with GSK6098, an ATP-competitive FAK inhibitor that has shown efficacy in animal models and is currently in clinical development (19).”
InfluentialLKB1 modulates lung cancer differentiation and metastasis
Ji, H., Ramsey, M. R., Hayes, D. N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M. C., Shimamura, T., Perera, S. A., et al. (2007) · Nature · doi:10.1038/nature06030 · Cited by 1,064
Skoulidis, F., Byers, L. A., Diao, L., Papadimitrakopoulou, V. A., Tong, P., Izzo, J., Behrens, C., Kadara, H., Parra, E. R., Canales, J. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1236 · Cited by 936 · cited 1×
“in addition to patients with functional inactivation of the LKB1-AMPK axis in LKB1 mutation-negative tumors (13), will benefit from FAK therapy.”
Koyama, S., Akbay, E. A., Li, Y. Y., Aref, A. R., Skoulidis, F., Herter-Sprie, G. S., Buczkowski, K. A., Liu, Y., Awad, M. M., Denning, W. L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1439 · Cited by 640
Shackelford, D. B., Abt, E., Gerken, L., Vasquez, D. S., Seki, A., Leblanc, M., Wei, L., Fishbein, M. C., Czernin, J., Mischel, P. S., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.12.008 · Cited by 585
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Chen, Z., Cheng, K., Walton, Z., Wang, Y., Ebi, H., Shimamura, T., Liu, Y., Tupper, T., Ouyang, J., Li, J., et al. (2012) · Nature · doi:10.1038/nature10937 · Cited by 446 · cited 1×
“resistant to both standard-of-care docetaxel and combination treatment with a MEK inhibitor (7).”
Self-citation
Cited by
Richardson, A. M., Havel, L. S., Koyen, A. E., Konen, J. M., Shupe, J., Wiles, W. G., Martin, W. D., Grossniklaus, H. E., Sica, G., Gilbert-Ross, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1776 · Cited by 227
“All Emory samples were sequenced using a workflow described (18).”
InfluentialSelf-citationThe AMPK-Related Kinases SIK1 and SIK3 Mediate Key Tumor-Suppressive Effects of LKB1 in NSCLC
Hollstein, P. E., Eichner, L. J., Brun, S. N., Kamireddy, A., Svensson, R. U., Vera, L. I., Ross, D. S., Rymoff, T. J., Hutchins, A., Galvez, H. M., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1261 · Cited by 168
“We first tested effects of inactivating SIK1 via intratracheal delivery of functionally titered, equivalent amounts of pSECC viruses harboring sgRNAs against SIK1, along with sgRNAs targeting LKB1 (Figure S2B) and control sgTom (non-specific sgRNA) or sgLacZ [30, 31] sgRNAs, into KrasG12D mice containing a conditional…”
BackgroundInfluentialAn LKB1–SIK Axis Suppresses Lung Tumor Growth and Controls Differentiation
Murray, C. W., Brady, J. J., Tsai, M. K., Li, C., Winters, I. P., Tang, R., Andrejka, L., Ma, R. K., Kunder, C. A., Chu, P., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1237 · Cited by 111
“Lkb1 loss has been shown to broaden the histological spectrum of lung tumors within mouse models, enabling the emergence of tumors with squamous, large cell, and mucinous differentiation (7,28,29,31).”
BackgroundNf1 loss promotes Kras-driven lung adenocarcinoma and results in Psat1-mediated glutamate dependence
Wang, X., Min, S., Liu, H., Wu, N., Liu, X., Wang, T., Li, W., Shen, Y., Wang, H., Qian, Z., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809856 · Cited by 33
LKB1 drives stasis and C/EBP-mediated reprogramming to an alveolar type II fate in lung cancer
Murray, C. W., Brady, J. J., Han, M., Cai, H., Tsai, M. K., Pierce, S. E., Cheng, R., Demeter, J., Feldser, D. M., Jackson, P. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28619-8 · Cited by 22
Metadata
- Authors
- Gilbert-Ross, M., Konen, J., Koo, J., Shupe, J., Robinson, B. S., Wiles, W. G., Huang, C., Martin, W. D., Behera, M., Smith, G. H., Hill, C. E., Rossi, M. R., Sica, G. L., Rupji, M., Chen, Z., Kowalski, J., Kasinski, A. L., Ramalingam, S. S., Fu, H., Khuri, F. R., Zhou, W., & Marcus, A. I.
- Venue
- JCI Insight
- Published
- 2017-03-09
- Volume
- 2
- Issue
- 5
- Pages
- e90487-e90487
- ISSN
- 2379-3708 (ISSN-L)
- OpenAlex
- W2594591478
- Cited by
- 57
- References
- 12
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting adhesion signaling in KRAS, LKB1 mutant lung adenocarcinoma. https://app.cochat.ai/papers/10.1172/jci.insight.90487
- The paper
- Gilbert-Ross, M., Konen, J., Koo, J., Shupe, J., Robinson, B. S., Wiles, W. G., Huang, C., Martin, W. D., Behera, M., Smith, G. H., Hill, C. E., Rossi, M. R., Sica, G. L., Rupji, M., Chen, Z., Kowalski, J., Kasinski, A. L., Ramalingam, S. S., Fu, H., . . . Marcus, A. I. (2017). Targeting adhesion signaling in KRAS, LKB1 mutant lung adenocarcinoma. JCI Insight. https://doi.org/10.1172/jci.insight.90487
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.